Bioventus (BVS) Total Non-Current Liabilities (2020 - 2026)

Bioventus (BVS) has reported Total Non-Current Liabilities for 7 consecutive years, with $382.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 20.96% year-over-year to $382.7 million; the trailing twelve-month figure through Jun 2026 stood at $382.7 million (down 20.96% YoY), and the FY2025 full-year result was $439.8 million, down 15.31% from the prior year.
• Total Non-Current Liabilities declined to $382.7 million in Q2 2026 per BVS's latest filing, from $402.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $937.6 million in Q4 2022 and bottomed at $382.7 million in Q2 2026.
• Historically, Total Non-Current Liabilities has averaged $575.9 million across 5 years, with a median of $555.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 138.18% in 2022, then sank 40.9% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $937.6 million in 2022, then sank by 40.08% to $561.9 million in 2023, then fell by 7.58% to $519.2 million in 2024, then fell by 15.31% to $439.8 million in 2025, then decreased by 12.97% to $382.7 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $382.7 million, $402.0 million, and $439.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.